OBJECTIVE: Women with gestational diabetes mellitus (GDM) demonstrate chronic and progressive insulin resistance and a markedly increased risk of converting to type 2 diabetes after pregnancy. However, the cellular mechanisms underlying this insulin resistance are unknown. RESEARCH DESIGN AND METHODS: We investigated the progression of insulin resistance in nine obese women with GDM during late pregnancy (30-36 weeks) and 1 year postpartum. Skeletal muscle biopsies were obtained at each visit, and insulin resistance was determined by the hyperinsulinemic-euglycemic clamp technique. RESULTS: Insulin resistance was not significantly improved in GDM women (4.1 +/- 0.4 vs. 5.8 +/- 1.1 10(-2) mg x kg FFM x min(-1)/microU x ml(-1)). Subjects did not experience significant weight loss postpartum. Body weight, fat mass, fasting glucose, and plasma tumor necrosis factor (TNF)-alpha remained higher 1 year postpartum than seen in previously studied normal glucose-tolerant women. Skeletal muscle TNF-alpha mRNA was elevated five- to sixfold in GDM women and remained higher 1 year postpartum. While levels of insulin receptor (IR), IR substrate (IRS)-1, and p85 alpha improved postpartum, insulin-stimulated IR tyrosine phosphorylation and receptor tyrosine kinase activity did not significantly improve postpartum in GDM. The levels of (312)Ser-IRS-1 also did not improve postpartum and correlated with TNF-alpha mRNA (r(2) = 0.19, P < 0.03), consistent with a state of subclinical inflammation and chronic skeletal muscle insulin resistance. CONCLUSIONS: These results suggest the mechanisms underlying chronic insulin resistance in GDM women may be driven by increased inflammation that impinges on the IR and IRS-1 signaling cascade in skeletal muscle. These findings have important implications for the health of GDM women during subsequent pregnancies and their risk for progression to type 2 diabetes.
OBJECTIVE:Women with gestational diabetes mellitus (GDM) demonstrate chronic and progressive insulin resistance and a markedly increased risk of converting to type 2 diabetes after pregnancy. However, the cellular mechanisms underlying this insulin resistance are unknown. RESEARCH DESIGN AND METHODS: We investigated the progression of insulin resistance in nine obesewomen with GDM during late pregnancy (30-36 weeks) and 1 year postpartum. Skeletal muscle biopsies were obtained at each visit, and insulin resistance was determined by the hyperinsulinemic-euglycemic clamp technique. RESULTS:Insulin resistance was not significantly improved in GDM women (4.1 +/- 0.4 vs. 5.8 +/- 1.1 10(-2) mg x kg FFM x min(-1)/microU x ml(-1)). Subjects did not experience significant weight loss postpartum. Body weight, fat mass, fasting glucose, and plasma tumor necrosis factor (TNF)-alpha remained higher 1 year postpartum than seen in previously studied normal glucose-tolerant women. Skeletal muscle TNF-alpha mRNA was elevated five- to sixfold in GDM women and remained higher 1 year postpartum. While levels of insulin receptor (IR), IR substrate (IRS)-1, and p85 alpha improved postpartum, insulin-stimulated IRtyrosine phosphorylation and receptor tyrosine kinase activity did not significantly improve postpartum in GDM. The levels of (312)Ser-IRS-1 also did not improve postpartum and correlated with TNF-alpha mRNA (r(2) = 0.19, P < 0.03), consistent with a state of subclinical inflammation and chronic skeletal muscle insulin resistance. CONCLUSIONS: These results suggest the mechanisms underlying chronic insulin resistance in GDM women may be driven by increased inflammation that impinges on the IR and IRS-1 signaling cascade in skeletal muscle. These findings have important implications for the health of GDM women during subsequent pregnancies and their risk for progression to type 2 diabetes.
Authors: Linda A Barbour; Jianhua Shao; Liping Qiao; Leslie K Pulawa; Dalan R Jensen; Andrzej Bartke; Maureen Garrity; Boris Draznin; Jacob E Friedman Journal: Am J Obstet Gynecol Date: 2002-03 Impact factor: 8.661
Authors: Shannon M Heitritter; Caren G Solomon; Gary F Mitchell; Nadia Skali-Ounis; Ellen W Seely Journal: J Clin Endocrinol Metab Date: 2005-04-19 Impact factor: 5.958
Authors: Linda A Barbour; Shaikh Mizanoor Rahman; Inga Gurevich; J Wayne Leitner; Stephanie J Fischer; Michael D Roper; Trina A Knotts; Yen Vo; Carrie E McCurdy; Shoshana Yakar; Derek Leroith; C Ronald Kahn; Lewis C Cantley; Jacob E Friedman; Boris Draznin Journal: J Biol Chem Date: 2005-09-08 Impact factor: 5.157
Authors: Robert V Farese; Mini P Sajan; Hong Yang; Pengfei Li; Steven Mastorides; William R Gower; Sonali Nimal; Cheol Soo Choi; Sheene Kim; Gerald I Shulman; C Ronald Kahn; Ursula Braun; Michael Leitges Journal: J Clin Invest Date: 2007-08 Impact factor: 14.808
Authors: N Jones; J Piasecka; A H Bryant; R H Jones; D O F Skibinski; Nigel J Francis; C A Thornton Journal: Clin Exp Immunol Date: 2015-07-24 Impact factor: 4.330
Authors: M L Erickson; J T Mey; C L Axelrod; D Paul; L Gordesky; K Russell; H Barkoukis; P O'Tierney-Ginn; R A Fielding; J P Kirwan; P M Catalano Journal: Contemp Clin Trials Date: 2020-05-08 Impact factor: 2.226
Authors: Jin Woo Lee; Il Seong Nam-Goong; Jae Geun Kim; Chang Ho Yun; Se Jin Kim; Jung Il Choi; Young Il Kim; Eun Sook Kim Journal: Korean Diabetes J Date: 2010-06-30
Authors: Thaddeus P Waters; Shin Y Kim; Andrea J Sharma; Pamela Schnellinger; Janet K Bobo; Robert T Woodruff; Lisa A Cubbins; Mary Haghiac; Judi Minium; Larraine Presley; Honor Wolfe; Sylvie Hauguel-de Mouzon; William Adams; Patrick M Catalano Journal: Diabetologia Date: 2019-12-09 Impact factor: 10.122